PDF herunterladen
Pharmacopsychiatry 2012; 45(04): 162-163
DOI: 10.1055/s-0031-1297933
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Agomelatine-Induced Akathisia with Concomitant Duloxetine Medication: A Case Report

C. Imboden
1   Psychiatric Services Solothurn, Department of Adult Psychiatry, Solothurn, Switzerland
,
M. Hatzinger
1   Psychiatric Services Solothurn, Department of Adult Psychiatry, Solothurn, Switzerland
2   Medical Faculty, University of Basel, Basel, Switzerland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 18. Mai 2011
revised 27. Oktober 2011

accepted 08. November 2011

Publikationsdatum:
30. Januar 2012 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

A 29-year-old depressed, otherwise healthy female patient was treated with agomelatine and duloxetine. She developed subsequent akathisia, which subsided after cessation of agomelatine. As a cause we suggest a pharmacodynamic drug-drug interaction leading to noradrenergic overstimulation. We recommend only gradual dose titration when combining the 2 substances to minimize the risk for side effects.

Key words

drug interaction - antidepressants - akathisia
 

  • References

  • 1 Sachdev P. The identification and management of drug-induced akathisia. CNS Drugs 1995; 4: 28-46
    CrossrefPubMedGoogle Scholar
  • 2 Madhusoodanan S, Alexeenko L, Sanders R et al. Extrapyramidal symptoms associated with antidepressants  −  a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 2010; 22: 148-156
    PubMedGoogle Scholar
  • 3 Bratti IM, Kane JM, Marder SR. Chronic restlessness with antipsychotics. Am J Psychiatry 2007; 164: 1648-1654
    CrossrefPubMedGoogle Scholar
  • 4 Koliscak LP, Makela EH. Selective serotonin reuptake inhibitor-induced akathisia. J Am Pharm Assoc. 2009 49: e28, 36; quiz e37-e38
    PubMedGoogle Scholar
  • 5 de Bodinat C, Guardiola-Lemaitre B, Mocaer E et al. Agomelatine, the first melatonergic antidepressant: Discovery, characterization and development. Nat Rev Drug Discov 2010; 9: 628-642
    PubMedGoogle Scholar
  • 6 Trivedi MH, Desaiah D, Ossanna MJ et al. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol 2008; 23: 161-169
    CrossrefPubMedGoogle Scholar
  • 7 McAllister-Williams RH, Baldwin DS, Haddad PM et al. The use of antidepressants in clinical practice: Focus on agomelatine. Hum Psychopharmacol 2010; 25: 95-102
    CrossrefPubMedGoogle Scholar
  • 8 Lobo ED, Bergstrom RF, Reddy S et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet 2008; 47: 191-202
    CrossrefPubMedGoogle Scholar
  • 9 Hiemke C, Baumann P, Bergemann N et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry 2011; 44: 195-235
    Google Scholar
  • 10 Stryjer R, Rosenzcwaig S, Bar F et al. Trazodone for the treatment of neuroleptic-induced acute akathisia: A placebo-controlled, double-blind, crossover study. Clin Neuropharmacol 2010; 33: 219-222
    CrossrefPubMedGoogle Scholar